Schelotto C, Santoni O, Nasini M G, Pietrucci A, Caviglia P M, Tirotta A, Repetto M, Carozzi S
U.O. di Nefrologia, Dialisi e Trapianto, ASL 2 Savonese, Presidio Ospedale San Paolo, Savona.
G Ital Nefrol. 2004 Nov-Dec;21 Suppl 30:S111-6.
This research aimed to compare two highly efficient dialysis techniques, paired filtration dialysis (PFD) and on-line hemodiafiltration with endogenous reinfusion (HFR) to evaluate the possible differences from a clinical, rehabilitative and managerial point of view.
The study was carried out on 14 patients (aged 40-65 yrs) six patients underwent PFD and eight patients underwent HFR. Patients on PFD came from low-flux hemodialysis (HD), while patients on HFR came either from PFD (n=5) or from low-flux HD (n=3). The research was based on the evaluation of patients inverted exclamation mark parameters (depurative and biochemical, level of clinical, medical and social rehabilitation) and of management parameters (technological aspects, cost analysis and medical-legal issues).
HFR treatment improved plasmatic albumin values (> or =4.0 g/dL) and had a lower resistance to recombinant human erythropoietin (rHuEPO) therapy (by reducing the rHuEPO doses to reach the maintenance target values of hemoglobin (Hb) although both therapies resulted in equal depurative efficiency, and improved patient rehabilitation.
This preliminary research, which requires further confirmation, demonstrates that HFR seems to provide PFD with other positive benefits and offers the uremic patient a better life style.
本研究旨在比较两种高效透析技术,即配对过滤透析(PFD)和在线血液透析滤过并内源性再输注(HFR),从临床、康复和管理角度评估可能存在的差异。
该研究针对14例患者(年龄40 - 65岁)进行,6例患者接受PFD,8例患者接受HFR。接受PFD的患者来自低通量血液透析(HD),而接受HFR的患者要么来自PFD(n = 5),要么来自低通量HD(n = 3)。该研究基于对患者参数(净化和生化、临床、医疗和社会康复水平)以及管理参数(技术方面、成本分析和医疗法律问题)的评估。
HFR治疗提高了血浆白蛋白值(≥4.0 g/dL),并且对重组人促红细胞生成素(rHuEPO)治疗的抵抗性较低(通过降低rHuEPO剂量以达到血红蛋白(Hb)的维持目标值),尽管两种治疗的净化效率相同,且改善了患者康复情况。
这项需要进一步证实的初步研究表明,HFR似乎为PFD带来了其他积极益处,并为尿毒症患者提供了更好的生活方式。